Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.74 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.50 |
| ▸ | DUT | P33316 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15160759 | 0.98 | KIF11 (0.71) | KIF11KCNN4DUTMAOAGRIN2D | |
| SCHEMBL1105545 | 0.85 | KIF11 (1.00) | KIF11KCNN4DUT | |
| SCHEMBL12264133 | 0.85 | KIF11 (0.68) | KIF11KCNN4DUT | |
| SCHEMBL12049184 | 0.84 | KIF11 (0.58) | KIF11KCNN4CHRM2 | |
| Bromide SCHEMBL5339582 | 0.83 | KIF11 (0.96) | KIF11KCNN4DUT | |
| SCHEMBL31229179 | 0.83 | KIF11 (0.61) | KIF11KCNN4DUT | |
| SCHEMBL3136435 | 0.83 | KIF11 (0.61) | KIF11KCNN4DUT | |
| SCHEMBL9617559 | 0.82 | KIF11 (0.78) | KIF11KCNN4DUT | |
| SCHEMBL4801600 | 0.82 | KIF11 (0.59) | KIF11KCNN4DUTMAOAGRIN1 | |
| SCHEMBL12264131 | 0.80 | KIF11 (0.74) | KIF11KCNN4DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732378-B2 | Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160194690-A1 | FLUOROPHORE CHELATED LANTHANIDE LUMINESCENT PROBES WITH IMPROVED QUANTUM EFFICIENCY | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-07-07 | — | — | US | disclosed |
| US-9358300-B2 | Transfection reagents | Life Technologies Corporation (US) | 2016-06-07 | — | — | US | disclosed |
| US-9358300-B2 | Transfection reagents | Life Technologies Corporation (US) | 2016-06-07 | — | — | US | disclosed |
| US-9221759-B2 | Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150190522-A1 | TRANSFECTION REAGENTS | LIFE TECHNOLOGIES CORP (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150190522-A1 | TRANSFECTION REAGENTS | LIFE TECHNOLOGIES CORP (US) | 2015-07-09 | — | — | US | disclosed |
| US-8785200-B2 | Transfection reagents | Life Technologies Corporation (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785200-B2 | Transfection reagents | Life Technologies Corporation (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130202536-A1 | FLUOROPHORE CHELATED LANTHANIDE LUMINESCENT PROBES WITH IMPROVED QUANTUM EFFICIENCY | NEW JERSEY INSTITUTE OF TECHNOLOGY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20070202598-A1 | NEW TRANSFECTION REAGENTS | INVITROGEN CORPORATION (US) | 2007-08-30 | — | — | US | disclosed |
| US-7173154-B2 | Transfection reagents | INVITROGEN CORP. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173154-B2 | Transfection reagents | INVITROGEN CORP. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7166745-B1 | Transfection reagents | INVITROGEN CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166745-B1 | Transfection reagents | INVITROGEN CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| CN-1146552-C | Azulene hydroxamic acid derivatives as metalloprotein inhibitors | �������ŵ˹�ٿ�˹�������ι�˾ | 2004-04-21 | — | — | CN | disclosed |
| CN-1281444-A | Azulene hydroxamic acid derivatives as metalloprotein inhibitors | ROTSCHIDEIGNOSTIKS AG (DE) | 2001-01-24 | — | — | CN | disclosed |
| EP-1054878-A1 | AZULENE HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEIN INHIBITORS | Roche Diagnostics GmbH (DE) | 2000-11-29 | — | — | EP | disclosed |
| US-6121322-A | ANTIINFLAMMATORY AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 2000-09-19 | — | — | US | disclosed |
| WO-1999031078-A1 | AZULENE HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEIN INHIBITORS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202598-A1 | NEW TRANSFECTION REAGENTS | PHAX, CPS1, HNRNPH3 | KIF11 4690/4885KCNN4 1659/4885DUT 628/4885 |
| US-20150190522-A1 | TRANSFECTION REAGENTS | CPS1, PHAX, HNRNPH3 | KIF11 4536/4885KCNN4 1855/4885DUT 490/4885 |
| US-20130202536-A1 | FLUOROPHORE CHELATED LANTHANIDE LUMINESCENT PROBES WITH IMPROVED QUANTUM EFFICIENCY | CLTA, LARS1, SSB | KIF11 839/4885KCNN4 1857/4885DUT 87/4885 |
| US-20160194690-A1 | FLUOROPHORE CHELATED LANTHANIDE LUMINESCENT PROBES WITH IMPROVED QUANTUM EFFICIENCY | CLTA, LARS1, SSB | KIF11 839/4885KCNN4 1857/4885DUT 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.